For this purpose, different SHP-1 inhibitors have been developed, displaying antitumor potential in advanced cancer patients, including melanoma patients [153,203,204,205], as demonstrated by two different clinical trials (Trial Number: NCT00629200 and NCT00498979; Table 1). Here, PTPN6 is linked to melanoma.